Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JDB153 + Penpulimab in Refractory Hepatocellular Carcinoma
NCT07075419Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of JDB153 in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
JDB153
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07075419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075419.